Waya News

Kuvomerezeka kwa Phunziro Latsopano Zotupa Zolimba ndi Non-Hodgkin Lymphoma

Written by mkonzi

Antengene Corporation Limited lero yalengeza kuti China National Medical Products Administration (NMPA) yavomereza kafukufuku wa Phase I wa ATG-101 (kafukufuku wa PROBE-CN) wochizira zotupa zapamwamba / zolimba za metastatic ndi B-cell non-Hodgkin lymphoma (B). -NHL).

ATG-101 ndi buku lotchedwa bispecific antibody lomwe lidapangidwa kuti liletse kumangiriza kwa immunosuppressive PD-1/PD-L1 ndikupangitsa kukondoweza kwa 4-1BB, motero kuyambitsa anti-chotupa chitetezo chamthupi, kwinaku ndikupititsa patsogolo ntchito yolimbana ndi chotupa, chitetezo mbiri yabwino. M'maphunziro a preclinical, ATG-101 adawonetsa zochitika zazikulu zotsutsana ndi chotupa m'zinyama za zotupa zosamva komanso zomwe zidapitilira chithandizo cha anti-PD-1/L1. Kuphatikiza apo, ATG-101 yawonetsanso mbiri yabwino yachitetezo mu maphunziro a GLP toxicology.

Chipatala cha Shanghai East cha ku yunivesite ya Tongji ndiye malo otsogolera kafukufukuyu, yemwe azichitika m'malo anayi ku China. Phunziro lotseguka, lokhala ndi magawo ambiri a Phase I lapangidwa kuti liwunike chitetezo ndi kulekerera kwa ATG-101 monotherapy yoyendetsedwa ndi mtsempha kwa odwala omwe ali ndi zotupa zapamwamba / zolimba zolimba ndi B-NHL. Phunziroli lidzachitidwa mu magawo awiri (kuwonjezeka kwa mlingo ndi kuwonjezereka kwa mlingo).

Pulofesa Ye Guo, Wachiwiri kwa Director of Medical Oncology pa chipatala cha Shanghai East ku yunivesite ya Tongji, Mtsogoleri wa chipatala cha mayeso a Phase I, komanso wofufuza wamkulu wa kafukufukuyu, adati: "Matenda omwe samva kapena kukana chithandizo chamankhwala (chemotherapy). , chithandizo chamankhwala, ndi immunotherapy, ndi zina zotero) ndizovuta kwambiri pochiza matenda ambiri. Odwala omwe ali ndi zotupa zotere amakhala ndi zosowa zachipatala zomwe sizikukwaniritsidwa. Umboni wochuluka umathandizira phindu lomwe lingakhalepo la ma antibodies a bispecific monga njira yodalirika yochizira zotupa zowopsa. ATG-101 ndi buku la PD-L1/4-1BB bispecific antibody. Linapangidwa kuti liphatikizepo kuyanjana kwakukulu kwa PD-L1 ndi kutsegula kwa 4-1BB, pofuna kuchepetsa chiopsezo cha 4-1BB chokhudzana ndi hepatoxicity. Ndizosangalatsa kwambiri kutsogolera kuyesa kwa PROBE-CN, kafukufuku woyamba wachipatala wa ATG-101 ku China. Gulu langa ligwira ntchito mosasunthika ndi ofufuza ena komanso gulu lofufuza la Antengene. Tikukhulupirira kuti ATG-101 ipereka njira yothandizira komanso yotetezeka kwa odwala omwe ali ndi zotupa zapamwamba. "

Dr. Jay Mei, Woyambitsa, Wapampando ndi Mtsogoleri wamkulu wa Antengene, adati: "Mukanthawi kochepa kwambiri, ATG-101 yapita patsogolo kuchokera ku pre-clinical kupita kuzinthu zosangalatsa, kuphatikizapo chilolezo cha IND ku Australia ndi US. , ndi chivomerezo chaposachedwa kwambiri cha NMPA ku China cha kafukufuku wa ATG-101 kwa odwala omwe ali ndi zotupa zapamwamba / zolimba za metastatic ndi B-NHL. Ndife okondwa kwambiri ndi zomwe pulogalamuyi yakwaniritsa ndipo tikukhulupirira kuti kafukufuku wofunikirawu athandiza kupititsa patsogolo chithandizo chamankhwala chothandiza kwa odwala omwe ali ndi zotupa zolimba komanso NHL omwe abwerera m'mbuyo kapena kukana chithandizo cha anti-PD-1/L1. ”

WTM London 2022 zidzachitika kuyambira 7-9 Novembala 2022. Lowetsani tsopano!

Nkhani Zogwirizana

Ponena za wolemba

mkonzi

Mkonzi wamkulu wa eTurboNew ndi Linda Hohnholz. Amakhala ku eTN HQ ku Honolulu, Hawaii.

Amamvera
Dziwani za
mlendo
0 Comments
Zolowetsa Pamakina
Onani ndemanga zonse
0
Mukufuna malingaliro anu, chonde yankhani.x
Gawani ku...